43rd week of 2015 patent applcation highlights part 11 |
Patent application number | Title | Published |
20150297699 | MALARIA ANTIGENS AND METHODS OF USE - The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against | 2015-10-22 |
20150297700 | Novel Adenovirus Vectors - An adenoviral vector comprising a promoter further comprising a fragment of the 5′ untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumour antigen for use as a medicament. | 2015-10-22 |
20150297701 | Interferon-beta Production Modulating Listeria Strains and Methods for Using Same | 2015-10-22 |
20150297702 | COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS - This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a human subject. | 2015-10-22 |
20150297703 | Bifidobacterium for dust mite allergy - A composition comprising | 2015-10-22 |
20150297704 | VACCINE TO PROTECT A RUMINANT AGAINST PNEUMONIA CAUSED BY PASTEURELLA MULTOCIDA - The present invention pertains to a vaccine comprising live attenuated | 2015-10-22 |
20150297705 | PREPARATION OF LIVE VACCINES - Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method. | 2015-10-22 |
20150297706 | Particulate Vaccine Formulations for Inducing Innate and Adaptive Immunity - Disclosed are compositions, kits, and methods for inducing an immune response against an infection or a disease. The compositions typically include biodegradable particles having an average effective diameter of 0.5-20 μm, and optionally the compositions include one or more of an adjuvant, an apoptosis inhibitor, and an antigen. The compositions, kits, and methods may be utilized to induce a cell-mediated response, such as a T-helper cell response, and/or a humoral response against a pathogen or a disease. In some embodiments, the compositions, kits, and methods may be utilized to induce preferentially a Th1 response versus other types of immune responses such as a Th2 response. | 2015-10-22 |
20150297707 | MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine, | 2015-10-22 |
20150297708 | MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine. | 2015-10-22 |
20150297709 | Porcine Circovirus Type 2 (PCV2), Immunogenic Composition Containing the Same, Test Kit, and Application Thereof - The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain. | 2015-10-22 |
20150297710 | EMULSION VACCINE COMPOSITIONS COMPRISING ANTIGEN AND ADJUVANT IN THE AQUEOUS PHASE - Emulsion vaccine formulations containing an antigen and an adjuvant in the aqueous phase are used for the vaccination of animals wherein the adjuvant is an acrylic polymer and/or dimethyl dioctadecyl ammonium bromide (DDA). These formulations can be prepared by mixing an aqueous phase containing the antigen and adjuvant with an oil phase in the presence of an emulsifier. | 2015-10-22 |
20150297711 | METHOD FOR ELICITING AN IMMUNE RESPONSE TO AN IMMUNOGEN - The invention relates to methods for eliciting an immune response to an immunogen, and in particular, to such methods using polymersomes as carriers for the immunogen. | 2015-10-22 |
20150297712 | INFLUENZA VIRUS VACCINES AND USES THEREOF - Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use. | 2015-10-22 |
20150297713 | RSV MUCOSAL VACCINE - A composition comprising the following composition: an AD vehicle including a synthetic peptide and a lipid, wherein the synthetic peptide includes the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20), a carboxylvinyl polymer and an RSV antigen. The composition has an antibody producing ability which is further higher than that of a conventional mucosal vaccine, hence capable of exerting excellent anti-virus antigen-specific IgA antibody- and IgG antibody-inducing effect in the nasal wash and the serum, respectively, even with an extremely small quantity of an RSV antigen. | 2015-10-22 |
20150297714 | NOVEL MUCOSAL ADJUVANTS AND DELIVERY SYSTEMS - Adjuvants comprising chitosan cross-linked with an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided. The adjuvant-antigen combinations can be used in vaccine formulations and the vaccine formulations can be used in methods to vaccinate animals against the source of the antigen or to enhance the immune response in a subject. | 2015-10-22 |
20150297715 | LECTIN COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE TO AN ANTIGEN - The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions. | 2015-10-22 |
20150297716 | COMPOSITIONS AND METHOD FOR LIGHT TRIGGERED RELEASE OF MATERIALS FROM NANOVESICLES - Provided are compositions comprising porphyrin-phospholipid nanovesicles (PoP-NVs) which can be loaded with cargo. Methods for release of cargo from the PoP-NVs triggered by near infrared (NIR) light are also disclosed. | 2015-10-22 |
20150297717 | PHARMACEUTICAL FORMULATIONS - The invention provides a pharmaceutical composition comprising (a) a compound of the formula (1), wherein R | 2015-10-22 |
20150297718 | IONTOPHORESIS DELIVERY OF CATIONIC PRODRUGS FOR TOPICAL TREATMENT OF MUSCULOSKELETAL OR SKIN DISEASES - The present invention provides a method for topical delivery of pharmacologically active chemicals into local tissues (skin, subcutaneous, muscle and joint tissues) via the administration of their specially designed cationic prodrugs with anode iontophoresis. The pharmacologically active chemicals are either negatively charged or neutral under the physiologic pH, which are not suitable to be delivered with the anode iontophoresis. The cationic prodrugs of such pharmacologically active chemicals are suitable for anode iontophoresis for improving delivery efficiency of these drugs into the local tissues. The cationic prodrugs can also be used in co-delivery with other cationic drugs such as vasoconstrictors or local anesthetic agents by iontophoresis for treatment of disorders in the local tissues. The anode iontophoresis delivery of the specially designed cationic prodrugs can provide higher drug concentrations in the local tissues, which can be used for better topical treatment of musculoskeletal diseases or skin diseases. | 2015-10-22 |
20150297719 | SYSTEMS, METHODS AND COMPOSITIONS FOR OPTICAL STIMULATION OF TARGET CELLS - Methods, systems and devices are implemented in connection with light-responsive ion channel molecules. One such method is implemented using a light- activated ion channel molecule that responds to a light stimulus. The method includes engineering the light-activated ion channel molecule in a cell; and activating the ion channel molecule, in response to light stimulus that is provided to the ion channel molecule and that has properties that do not activate a ChR2 ion channel, to allow ions to pass through the light-activated ion channel molecule. | 2015-10-22 |
20150297720 | PHOTODYNAMIC DIAGNOSTIC AGENT AND PHOTOBLEACHING INHIBITOR - The objects of the present invention are to inhibit photobleaching of porphyrins as well as to provide a superior photodynamic diagnostic agent and a photodynamic diagnostic method employing the photobleaching inhibitor for porphyrins. The present invention provides a photodynamic diagnostic agent containing a precursor of porphyrins and a gallic acid. The present invention also provides a photobleaching inhibitor for porphyrins containing a gallic acid. | 2015-10-22 |
20150297721 | COMPOSITIONS COMPRISING SPICAMYCIN DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to compositions comprising spicamycin derivatives, methods of making such compositions, and their use in the treatment and/or prevention of pain, including neuropathic pain. | 2015-10-22 |
20150297722 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH IMPROVED DISSOLUTION AND/OR ABSORPTION - This invention relates to a pharmaceutical composition for oral administration comprising 4-((1-methylpyrrol-2-yl)-carbonyl)-N-(4-(4-morpholin-1-yl-carbonylpiperidin-1-yl)-phenyl)-1-piperazinecarboxamide, a salt thereof, or a solvate thereof, as an active pharmaceutical ingredient; and at least one acid additive selected from the group consisting of adipic acid, succinic acid, fumaric acid, L-aspartic acid, and L-glutamic acid. | 2015-10-22 |
20150297723 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS - The present disclosure is drawn to topical formulations and related methods. In one embodiment, a topical formulation is provided that includes at least one corticosteroid, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate. | 2015-10-22 |
20150297724 | STABILIZED PEMETREXED FORMULATION - The present invention relates to a stabilized pemetrexed formulation, and more particularly to a stabilized pemetrexed formulation comprising acetylcysteine as antioxidant and a citrate salt as buffer. | 2015-10-22 |
20150297725 | COCHLEATES MADE WITH SOY PHOSPHATIDYLSERINE - Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B. | 2015-10-22 |
20150297726 | SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF GNRH ANALOGUES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue. | 2015-10-22 |
20150297727 | SAPONIN NANO MICELLE, PREPARING METHOD, APPLICATION AND PHARMACEUTICAL COMPOSITION THEREOF - A saponin nano micelle, preparing method, application and pharmaceutical composition thereof is disclosed in the present invention. The saponin nano micelle comprises one or more of saponins represented by formula 1, in which, R | 2015-10-22 |
20150297728 | METHOD OF STABILIZING FOAM IN ALCOHOL-BASED HAND SANITIZERS USING DIMETHICONE POLYOLS AND ALKYLENE OXIDE POLYMERS AS ADJUVENTS - A method of stabilizing alcohol-based hand sanitizers comprising providing a first composition of matter that is a combination of a linear dimethicone copolyol, an alkylene oxide adjuvant selected from the group consisting of polyethylene oxide, and, polypropylene oxide, and, an alcohol, then, combining the first composition of matter with an alcohol-based hand sanitizer. A composition of matter comprising linear dimethicone copolyol, an alkylene oxide adjuvant selected from the group consisting of polyethylene oxide, and, polypropylene oxide, and, an alcohol, and, a further composition of matter comprising linear dimethicone copolyol, an alkylene oxide adjuvant selected from the group consisting of polyethylene oxide, and, polypropylene oxide, and, an alcohol combined with an alcohol-based hand sanitizer. | 2015-10-22 |
20150297729 | LONG-ACTING POLYMERIC DELIVERY SYSTEMS - Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural). | 2015-10-22 |
20150297730 | COMPOSITIONS OF A POLYORTHOESTER AND AN ORGANIC ACID EXCIPIENT - Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an organic acid excipient, and a basic drug are described, along with related methods. | 2015-10-22 |
20150297731 | THERMOSENSITIVE INJECTABLE GLAUCOMA DRUG CARRIER GEL AND THE FABRICATING METHOD THEREOF - The present invention relates to a thermosensitive injectable glaucoma drug carrier gel and the fabricating method thereof. The thermosensitive injectable glaucoma drug carrier gel comprises: a polymer substrate comprising chitosan with hydrophilic and hydrophobic modification; an additive dispersed in the substrate, wherein the additive comprises a water/fat soluble glaucoma drug, a preservative, a solvent selected from glycerol, dimethyl sulfoxide (DMSO), ethanol, glycol or any combination thereof, and a basic structural stabilizer; and water. | 2015-10-22 |
20150297732 | BIODEGRADABLE MICROBEAD COMPRISING ANIONIC POLYMER FOR IMPROVING ADSORPTIVE POWER TO ANTICANCER DRUGS, AND METHOD FOR PREPARING SAME - The present invention relates to a biodegradable microbead having improved adsorptive power to anticancer drugs, to a method for preparing same, and to a method for treating cancer using same. According to the present invention, a rigid bead having excellent adsorptive power to anticancer drugs can be prepared through cross-linking and an amide bond between an albumin and an anionic polymer. Also, the microbead of the present invention is prepared by a biocompatible and biodegradable polymer so as to be safe when applied to the human body. Further, the microbead of the present invention can effectively inhibit the growth of a tumor by effectively blocking a blood vessel which supplies nutrients to a liver tumor, while continuously releasing anticancer drugs which are adsorbed into the surface of the bead. Thus, the present invention can be usefully applied to a chemoembolization of liver cancer. | 2015-10-22 |
20150297733 | CONTROLLED RELEASE TOPICAL TESTOSTERONE FORMULATIONS AND METHODS - The present invention relates to testosterone topical formulations, especially high testosterone concentration formulations, such as between about 6% to about 15% w/w or higher, for the controlled release of testosterone into the systemic circulation of males and females for providing constant effective testosterone blood levels, without inducing undesired testosterone spike in blood levels or testosterone transference, following topical administration. The present invention also relates to methods and pre-filled multi-dose airless applicator systems for pernasal administration of the nasal testosterone gels of the present invention | 2015-10-22 |
20150297735 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS - The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells. | 2015-10-22 |
20150297737 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV - The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds. | 2015-10-22 |
20150297738 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION - The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS′(-L-M) | 2015-10-22 |
20150297739 | DEVELOPMENT OF A HIGHLY EFFICIENT SECOND GENERATION NICOTINE-CONJUGATE VACCINE TO TREAT NICOTINE ADDICTION - The invention is directed to a conjugate which comprises an isolated adenovirus hexon protein coupled to nicotine or a nicotine analog, as well as a method of inducing an immune response against nicotine in a human by using the conjugate. | 2015-10-22 |
20150297740 | VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions - The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions. | 2015-10-22 |
20150297741 | BIO-ORTHOGONAL DRUG ACTIVATION - Disclosed is a kit for the administration and activation of a Prodrug. The kit comprises a Masking Moiety linked, directly or indirectly, to a Trigger moiety, which in turn is linked to a Drug, and an Activator for the Trigger moiety. The Trigger moiety comprises a dienophile and the Activator comprises a diene, whereby the dienophile is an eight-membered non-aromatic cyclic alkenylene group, preferably a cyclooctene group, and more preferably a trans-cyclooctene group. The Trigger and the Activator undergo a fast, bio-orthogonal reaction resulting in the release of the Masking Moiety, and activation of the drug. | 2015-10-22 |
20150297742 | Conjugates of Proteins and Multivalent Cell-Penetrating Peptides and Their Uses - The present invention relates to conjugates comprising a protein and multivalent cell-penetrating peptide(s), each multivalent cell-penetrating peptide comprising at least two cell-penetrating peptides, wherein the multivalent cell-penetrating peptide(s) is/are covalently attached to the protein. The present invention furthermore relates to a method of generating the conjugates and to their medical uses, in particular their use in the diagnosis, prevention and/or treatment of diseases. The present invention relates to methods of diagnosis, prevention and/or treatment of diseases, comprising administering the conjugates of the invention to a patient. | 2015-10-22 |
20150297743 | LY75 AS CANCER THERAPEUTIC AND DIAGNOSTIC TARGET - The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer, such as lymphoma, myeloma, leukaemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer, for monitoring the effectiveness of cancer, such as lymphoma, myeloma, leukaemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer treatment, and for drug development. | 2015-10-22 |
20150297744 | Anti-FOLR1 Immunoconjugate Dosing Regimens - Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects. | 2015-10-22 |
20150297745 | Agents and Methods - The invention provides an agent comprising: (i) a T cell antigen, and (ii) a binding partner for any of CD22, CD23, CD30, CD74, CD70, CD43, CD44, CD47, CD54, CD58, CD62L, CD95, HLA-DR, CD59, CD55, wherein, following binding of the agent to a cell that expresses any of CD22, CD23, CD30, CD74, CD70, CD43, CD44, CD47, CD54, CD58, CD62L, CD95, HLA-DR, CD59, CD55, the agent is internalised and the T cell antigen is presented on the surface of the cell in a form that can be recognised by a T cell. | 2015-10-22 |
20150297746 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES - Conjugates of an antibody that binds to CD25 with PBD dimers. | 2015-10-22 |
20150297747 | TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF - Provided herein are trioxacarcin-antibody drug conjugates of Formula (A): and pharmaceutically acceptable salts thereof, comprising at least one instance of the group -L | 2015-10-22 |
20150297748 | ANTIBODY-DRUG CONJUGATE - As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: | 2015-10-22 |
20150297749 | LOW-DENSITY LIPOPROTEIN ANALOGUE NANOPARTICLES, AND COMPOSITION COMPRISING SAME FOR TARGETED DIAGNOSIS AND TREATMENT OF LIVER - This disclosure relates to a low density lipoprotein-like cationic solid lipid nanoparticle targeting liver cells including parenchyma cells and non-parenchyma cells, a composition for liver target delivery, a composition for diagnosis and/or treatment of liver disease comprising the same, and a method for liver targeting of an active ingredient. | 2015-10-22 |
20150297750 | THERAPEUTIC AND VACCINE POLYELECTROLYTE NANOPARTICLE COMPOSITIONS - Polyelectrolyte nanoparticle compositions for biomedical applications are provided comprising at least two carrier domains comprising multivalent ionic domains and an agent exhibiting biological activity when contained within the nanoparticle or on the nanoparticle surface. The multivalent ionic domains may be contained in two separate molecules or in separate but linked domains of a single molecule. The nanoparticle optionally can further comprise an exposed targeting ligand and/or protective surface. The nanoparticle can be contacted to cells or administered directly to an animal for biomedical applications including therapeutics and immune response. The nanoparticle may alternatively be comprised of a carrier material capable of delivering various medically important antigens as vaccine. | 2015-10-22 |
20150297751 | DRUG DELIVERY PARTICLE FORMULATIONS WITH TARGETING MOIETIES - A targeted drug delivery complex containing a particle, a targeting moiety electrostatically attached to the particle, and an active pharmaceutical ingredient attached to or dispersed or dissolved within the particle is provided. Also provided are pharmaceutical formulations containing a plurality of the complexes as well as methods for use in targeting an active pharmaceutical ingredient to a selected cell or tissue and production of such formulations. | 2015-10-22 |
20150297752 | AQUEOUS ORAL SOLUTIONS OF STEROID HORMONES AND HYDROXYPROPYL-BETA-CYCLODEXTRIN WITH OPTIMISED BIOAVAILABILITY - The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-3-cyclodextrin (HPβCD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HPβCD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bio availability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients. | 2015-10-22 |
20150297753 | COMPOSITIONS FOR DELIVERY OF ORAL COMFORT SENSATIONS - TREK-1 agonist comprising composition that reduces perceived oral discomfort sensation and a method for measuring TREK-1 potassium channel activation. | 2015-10-22 |
20150297754 | ANIMAL MODEL OF NEURONAL INJURY - The present invention provides non-human animal models of neuronal injury and/or cognitive dysfunction and methods of making and using such animal models. The animal models of the invention are particularly suited to assessing neurodegeneration in selected regions of interest in the CNS, and thus especially useful for testing the therapeutic efficacy of agents targeting neurodegeneration associated with aging, neurodegenerative diseases, autoimmunity and trauma (e.g., ischemia). | 2015-10-22 |
20150297755 | FLUORESCENCE COLORING FOR EYE SURGERY - Disclosed herein is a method of use of colored dye in ophthalmic surgery. In one embodiment the colored dye is fluorescent. In another embodiment the fluorescent dye is combined with viscoelastic gel for anterior segment eye surgery. | 2015-10-22 |
20150297756 | Protein-Based Nanobubble X-Ray Imaging Method and Agent - Systems, compositions, methods and kits employ protein shells, such as ferritin or viral capsid shells, herein called nanobubbles, to enhance X-ray images of cells or body tissue under certain x-ray imaging methods. The nanobubbles have sub-micron size such as about 10 nm, about 40, 60, or 100 nm and may be functionalized for effective delivery to or uptake by a target tissue, in vivo or a cell culture. The nanobubbles are hollow, having a central core which may be empty or contain a fluid, such that the shells effectively form long-lived bubbles in the imaged environment, and are of low electron density and have different scattering properties than the surrounding tissue. X-ray imaging by spatial frequency heterodyne imaging enhances visualization or detection of tissue regions bearing the shells. The protein shells may be further treated to assure biocompatibility and/or to resist undesired interactions with non-targeted tissue, such as scavenging by the liver, or attack by the immune system. For example the nanobubbles may be filled with a hydrophobic gas such as perfluoropropane (octafluoropropane) to maintain their shape and resist hydrophilic interactions and delay the degradation of the protein shells. The nanobubbles may also be coated or treated by a surface-functionalization processes to effectively target specific tissues or tumor types, allow parenteral delivery, and/or deliver drugs or other agents to the imaged sites—so that when visualized by X-ray scatter imaging the presence of the nanobubbles indicates the existence and extent of the tumor or diseased tissue. | 2015-10-22 |
20150297757 | MACROPHAGE-ENHANCED MRI (MEMRI) IN A SINGLE IMAGING SESSION - Methods for performing macrophage-enhanced MRI, utilizing a macrophage imaging agent, in a single imaging session are provided. The macrophage imaging agent may be an ultrasmall superparamagnetic iron oxide particle. One embodiment includes administering a macrophage imaging agent to the subject during an administration session then allowing a passage of time sufficient for accumulation of the agent in macrophages of the subject. Subsequently, in a single imaging session, a macrophage-enhanced magnetic resonance image is acquired to target macrophages and a different magnetic resonance image is acquired to target physiological phenomenon other than macrophages. Additional embodiments provide methods wherein the acquisition of a different magnetic resonance image is achieved by vascular-enhanced MRI protocols or perfusion-enhanced MRI protocols, or combinations thereof. Further embodiments provide methods for utilizing acquired images in assessment of treatment of disease. | 2015-10-22 |
20150297758 | MAGNETITE IN NANOPARTICULATE FORM - The present invention relates to a process for the polyol-type synthesis of nanoparticulate magnetite starting from mixtures of Fe | 2015-10-22 |
20150297759 | NOVEL FLUORINE-18 LABELED RHODAMINE DERIVATIVES FOR IMAGING WITH POSITRON EMISSION TOMOGRAPHY - The present invention is directed toward novel fluorine-18 labeled rhodamine dye derivatives and methods of making the same. The present invention is also directed toward methods of using novel fluorine-18 labeled rhodamine dye derivatives as positron emission tomography imaging agents and myocardial perfusion imaging agents. | 2015-10-22 |
20150297760 | 18F LABELED BODIPY DYE AND ITS DERIVATIVES FOR PET IMAGING OF HEART PERFUSION AND OTHERS - This invention provides a class of dual mode imaging tracer capable of acting both as a fluorescent imaging tracer and a positron emission tomography imaging tracer. Tracers in accordance with this invention generally have a fluorescent core with a boron-fluoride element embedded therein. Exemplary embodiments of the tracer include | 2015-10-22 |
20150297761 | PEPTIDIC STRUCTURES INCORPORATING AN AMINO ACID METAL COMPLEX AND APPLICATIONS IN MAGNETIC RESONANCE IMAGING - A method for increasing the relaxivity of a contrast agent having a metal ion complexed to a chelator is disclosed. The metal ion complex is tethered to the remainder of the molecule by at least two points of attachment such that local motion is limited and higher relaxivity can be achieved. In one non-limiting example version of the invention, the alanine analogue of Gd(DOTA), Gd(DOTAla) wherein Gd is gadolinium and DOTA is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid was integrated into polypeptide structures. This resulted in very rigid attachment of the metal ion complex to the peptide backbone. Rigid molecular structures provide fewer degrees of rotational freedom, resulting in greater control over the rotational dynamics and resultant relaxivity. In the case of Gd(DOTAla), the metal complex is tethered to the peptide via the amino acid side chain to the DOTA moiety and via a dative bond from an amide oxygen to the Gd(III) ion. | 2015-10-22 |
20150297762 | MONOCLONAL ANTIBODY DS6, TUMOR-ASSOCIATED ANTIGEN CA6, AND METHODS OF USE THEREOF - The present application describes a monoclonal antibody selected from the group consisting of monoclonal antibody DS6, monoclonal antibodies that specifically bind to the antigen or epitope bound by monoclonal antibody DS6, and fragments of the foregoing that specifically bind to the antigen or epitope bound by monoclonal antibody DS6. Methods of use of such antibodies and the isolated antigen bound by such antibodies are also described. | 2015-10-22 |
20150297763 | DEVICES AND METHODS FOR THERAPEUTIC HEAT TREATMENT - A microparticle includes a plurality of magnetic nanoparticles having a Curie temperature between 40° and 100° C. The microparticle further includes a biocompatible polymer and/or biocompatible ceramic and a plurality of radiopaque nanoparticles. | 2015-10-22 |
20150297764 | SYSTEMS, METHODS, AND DEVICES FOR STERILIZING ANTISEPTIC SOLUTIONS - A method for sterilizing an antiseptic solution includes providing a plurality of containers containing the antiseptic solution, the antiseptic solution having an initial purity, selecting a sterilization temperature from about 85° C. to about 135° C. and an sterilization time from about 1 minute to about 19 hours, heating the antiseptic solution in the plurality of containers to the selected sterilization temperature, maintaining the temperature for the selected sterilization time, and terminating the heating of the antiseptic solution when the sterilization time expires. After terminating the heating, the antiseptic solution in the plurality of containers has a post-sterilization purity. The sterilization temperature and the sterilization time are selected such that after terminating the heating, the antiseptic solution is sterile and have a post-sterilization purity of at least about 92% and the percentage point change in purity from the initial purity to the post-sterilization purity is at most about 5%. | 2015-10-22 |
20150297765 | APPARATUS AND METHOD FOR STERILIZING CONTAINERS WITH X-RAY RADIATION MONITORING - An apparatus for sterilizing containers includes a transport device which transports the containers along a predefined transport path (P), a radiation device which applies radiation (S) to at least some sections of the containers and/or components of the apparatus for sterilization purposes, and a sensor device which detects radiation occurring as a result of the radiation (S) emitted by the radiation device. The apparatus has a shielding element which attenuates the radiation reaching the sensor device in a working mode of the apparatus, and a movement device for moving said shielding element relative to the sensor device. | 2015-10-22 |
20150297766 | PORTABLE LIGHT FASTENING ASSEMBLY - A portable light fastening assembly for use with the human interface of an electronic device includes a lamp housing and an adjustable attachment device extending from the lamp housing. An ultra-violet (UV) light source is at least partially enclosed in the lamp housing such that the adjustable attachment device includes an engagement member and a receptacle housing such that the engagement member can be removably fastened within the receptacle housing for holding the lamp housing in a fixed position. | 2015-10-22 |
20150297767 | Ultraviolet-Based Sterilization - A system for sterilizing at least one surface of an object is provided. The system includes a set of ultraviolet radiation sources and a set of wave guiding structures configured to direct ultraviolet radiation having a set of target attributes to a desired location on at least one surface of the object. The set of wave guiding structures can include at least one ultraviolet reflective surface having an ultraviolet reflection coefficient of at least thirty percent. Furthermore, the system can include a computer system for operating the ultraviolet radiation sources to deliver a target dose of ultraviolet radiation to the at least one target surface of the object. | 2015-10-22 |
20150297768 | Flexible Ultraviolet Device - A solution in which an ultraviolet radiation source is mounted on a flexible substrate is provided. The flexible substrate is capable of having a deformation curvature of at least 0.1 inverse meters. The flexible substrate may be incorporated within an existing enclosure or included in the enclosure. The flexible substrate can be utilized as part of a solution for disinfecting one or more items located within the enclosure. In this case, while the items are within the enclosure, ultraviolet radiation is generated and directed at the items. Wiring for the ultraviolet radiation source can be embedded within the flexible substrate and the flexible substrate can have at least one of: a wave-guiding structure, an ultraviolet absorbing surface, or an ultraviolet reflective surface. A control system can be utilized to manage generation of the ultraviolet radiation within the enclosure. | 2015-10-22 |
20150297769 | SYSTEM AND METHOD FOR PROBE CLEANING AND DISINFECTING - Embodiments of the invention are directed to apparatuses and methods for cleaning and disinfecting probes. A cleaner is utilized to remove foreign materials (e.g., bioburden, soil, and other like material) from the probe after it is removed from the patient by soaking and/or flushing the foreign materials from the probe. The cleaner may be an enzymatic detergent that has bacteriostatic properties to inhibit bacterial growth within the apparatus. The multiple enzymes in the cleaner attack the foreign material, and include low-foam properties for effective recirculation across cycles within the cleaning step. The probe is rinsed after the cleaning step, and after rinsing a disinfectant process is applied to the probe. The disinfectant soaks and/or flushes the probe for a specified amount of time across cycles of recirculation to disinfect the surface of the probe, and afterwards the probe is rinsed thoroughly to remove the disinfectant from the probe. | 2015-10-22 |
20150297770 | TWO-PART DISINFECTANT SYSTEM AND RELATED METHODS - The present disclosure is drawn to a disinfectant system which can be used to disinfect surfaces. The system includes a first chamber containing a first solution and a second chamber containing a second solution. The first solution can include an alcohol, an organic carboxylic acid, and from 0.01 ppm, to 1,000 ppm by weight of a transition metal or alloy thereof based on the first solution weight content. The second solution can include hydrogen peroxide. The system further includes a dispenser through which the system is configured to mix and dispense the first solution and the second solution immediately before being dispensed. A peracid composition is formed upon mixing of the first and second solutions. | 2015-10-22 |
20150297771 | METHOD AND APPARATUS FOR HIGH EFFICIENCY AIR PURIFICATION - The present invention discloses an air purification apparatus. The air purification apparatus comprising: a casing which contains at least one apparatus air inlet and at least one apparatus air outlet; at least one main filter which is being installed at the apparatus air inlet and/or within the casing; at the periphery of the main filter, there locates a primary air flow inlet and a secondary air flow inlet. When a primary air flow is drawn to flow from the upstream to the downstream positions inside the casing, the primary air flow is adapted to pass by at least one edge of the exterior of the main filter, resulting at least two exterior surfaces of the main filter being exerted with different atmospheric pressures. Through the secondary air flow inlet, a secondary air flow is entrained through the main filter and flows from its exterior surface is exerted with higher atmospheric pressure to its exterior surface is exerted with lower atmospheric pressure. The invention offers an air purification apparatus which owns the characteristics of simple structure, able to extend the life-span of the filter cost effectively, low energy consumption and induced low noise level. | 2015-10-22 |
20150297772 | COMPOSITION FOR ODOR REMOVAL AND FRAGRANCE EMISSION COMPRISING COMPLEXES OF CUCURBITURIL AND FRAGRANCE - Disclosed herein is a composition for removing an odor molecule and releasing a fragrant molecule, the composition including a complex of cucurbituril and a fragrant molecule. The composition is characterized in that an odor molecule and a fragrant molecule alternately make a complex with cucurbituril, so the odor molecule makes a complex with cucurbituril, and, simultaneously, the fragrant molecule is released from the complex. The composition provides very efficient air cleaning effects because it can exhibit both an odor removing effect and a fragrant molecule releasing effect using only cucurbituril which is a single-kind macrocyclic molecule. | 2015-10-22 |
20150297773 | Aroma Emitting Kit System - An aroma emitting kit system allows a person to light incense safely and easily. The system includes a housing having a striking surface positioned thereon. At least one incense device is provided. Each incense device is positionable within the housing to store the incense devices therein. Each of the incense devices includes a head and a main body coupled to the associated head. The head is ignitable and generates a flame when the head is struck against the striking surface. The main body has an incense material positioned therein. The incense material is scented and positioned adjacent to the head such that igniting the head heats the incense material and causes the incense material to emit a fragranced odor. | 2015-10-22 |
20150297774 | FRAGRANCE DELIVERY SYSTEM, DEVICES, AND METHODS - This application generally relates to systems, devices, and methods for delivering a fragrance. In some embodiments, portable fragrance delivery systems are provided. In further embodiments, improved fragrance delivery systems are provided that provide increased dispersion of scented agents. In some embodiments, a fragrance delivery system does not include a light source. Optionally, the fragrance delivery system does not include a heater. A portable power source (e.g., disposable or rechargeable batteries) may be provided to power a fan. The fan may blow air through channels of a fragrance carrier to disperse the vaporizing agent and/or scent released by the fragrance carrier. | 2015-10-22 |
20150297775 | REMOVABLE CARTRIDGE FOR LIQUID DIFFUSION DEVICE AND CARTRIDGE INSERT THEREOF - An insert of a cartridge for use with a liquid diffusing device is provided. The insert includes a body, an inlet provided in the body to receive diffused liquid generated within the cartridge during operation of the liquid diffusing device, an outlet zone defined at least in part by the body through which to discharge the diffused liquid toward an external environment, and a tortuous passage extending between the inlet and the outlet zone to aid in further reducing an average particle size of the diffused liquid as the diffused liquid moves through the tortuous passage. Removable cartridges for use with a diffusion device are also provided which include such an insert. | 2015-10-22 |
20150297776 | METHOD AND SYSTEM OF A NETWORK OF DIFFUSERS INCLUDING A LIQUID LEVEL SENSOR - Systems and methods for managing scent in an environment include disposing a plurality of scent diffusion devices within an environment, wherein the diffusion devices include a communications facility that enables transmitting signals to and receiving signals from a remote computer and disposing at least one sensor within the environment that transmits sensor data to the remote computer. At least one scent parameter for scenting an environment is received at the remote computer. The remote computer controls diffusion of a liquid from a source of a liquid in fluid communication with at least one of the plurality of scent diffusion devices to achieve the scent parameter. Controlling includes setting or adjusting an operation parameter of the scent diffusion device in response to the sensor data. | 2015-10-22 |
20150297777 | METHOD AND SYSTEM FOR SWITCHING BETWEEN PACKAGES IN A DIFFUSION DEVICE BASED ON A LIQUID LEVEL SENSOR - The disclosure herein concerns an atomizing diffusion device including at least two packages with liquid in fluid communication with the atomizing diffusion device, a liquid level sensor that determines the liquid level in the package, and a processor, operatively coupled to the liquid level sensor, for generating a signal indicative of the liquid level and a control instruction for a switch based on the signal, wherein the switch, operatively coupled to the processor, receives the control instruction from the processor, and wherein the control instruction causes the diffusion device to switch from utilizing one package in the diffusion device to utilizing a different package in the diffusion device. | 2015-10-22 |
20150297778 | METHOD AND SYSTEM OF SENSOR FEEDBACK FOR A SCENT DIFFUSION DEVICE - The disclosure herein concerns a method including receiving at a computer at least one target value of a scent parameter for an environment that is remote from the computer, receiving at the computer a sensed parameter of the environment, and controlling, via the computer, diffusion of a liquid from a source of the liquid in fluid communication with at least one scent diffusion device to achieve the target value of the scent parameter, wherein controlling includes setting or adjusting an operation parameter of the at least one scent diffusion device in response to the sensed parameter. | 2015-10-22 |
20150297779 | METHOD AND SYSTEM OF IDENTIFYING TAMPERING IN A SCENT MANAGEMENT SYSTEM - Scent cartridges for use in a networked scent diffusion device include a reservoir that holds a liquid and an atomizer head assembly. An anti-tampering identifier is associated with at least one of the reservoir and the atomizer head assembly. Scent diffusion from the device is based on the condition of the anti-tampering identifier. | 2015-10-22 |
20150297780 | COMPRESSED GAS AEROSOL COMPOSITION IN STEEL CAN - An aqueous compressed gas aerosol formulation in combination with a lined steel can, which may also optionally be tin plated, to provide corrosion stability, fragrance stability and color stability. An aerosol formulation of particular advantage for use is an air and/or fabric treatment formulation. The combination provides a compatibility which allows for the ability to use a broader fragrance pallet for the air and/or fabric treatment formulation which is aqueous based in major proportion. The formulation includes, in addition to an aqueous carrier, a fragrance, nonionic surfactant(s) or a blend of nonionic surfactant(s) and cationic surfactant(s), a compressed gas propellant(s), pH adjuster(s), and corrosion inhibitor(s). The formulation has a pH of about 8 to less than 10. The corrosion inhibitor(s) is(are) mild in strength and used in a minor amount. | 2015-10-22 |
20150297781 | ABSORBENT AND ABSORBENT ARTICLE PROVIDED THEREWITH - The present invention addresses the problem of providing a novel absorbent that comprises a water-absorbing cellulose-based fiber and a thermoplastic resin fiber, said thermoplastic resin fiber containing as a monomer component an unsaturated carboxylic acid or an unsaturated carboxylic acid anhydride, and has both a sufficient strength and a sufficient absorption property. The absorbent comprises a water-absorbing cellulose-based fiber and a thermoplastic resin fiber, said thermoplastic resin fiber containing as a monomer component an unsaturated carboxylic acid or an unsaturated carboxylic acid anhydride, wherein the mass ratio (the content of the water-absorbing cellulose-based fiber: the content of the thermoplastic resin fiber) is controlled to 90:10 to 50:50 and the density of the absorbent is controlled to 0.06 to 0.14 g/cm | 2015-10-22 |
20150297782 | NITRIC OXIDE-RELEASING DRESSINGS - A wound dressing comprising nitric oxide gas producing component. | 2015-10-22 |
20150297783 | COMPOSITION, PREPARATION, AND USE OF CHITOSAN SHARDS FOR BIOMEDICAL APPLICATIONS - A thin chitosan-based material can be used for biomedical applications. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan material. A single or multiple such treatments may be employed. For example, the chitosan material may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both. A thin chitosan material can be readily treated by surface modifying treatments such as irradiating under nitrogen using γ-irradiation, treating under a nitrogen plasma, or both. | 2015-10-22 |
20150297784 | IMIDATED BIOPOLYMER ADHESIVE AND HYDROGEL - Biologically compatible polymers carry an imide and can be used as an adhesive, a hydrogel or both. A second biologically compatible polymer reactive with the imidated polymer can be used therewith to seal openings. | 2015-10-22 |
20150297785 | Wound Healing Material And Application Thereof - The present invention provides a wound healing material and its application thereof. The wound healing material comprises a hydrophobic fluoro-containing membrane having a first surface and a second surface opposing to each other; and at least one biocompatible polymer covalently bonded to at least one part of the first surface of the membrane wherein the membrane is air permeable but liquid impermeable and the water contact angle of the first surface formed with the biocompatible polymer is smaller than or equal to 40 degrees. | 2015-10-22 |
20150297786 | Fenestrated Hemostatic Patch - A hemostat comprises a non-porous patch made of a bio-resorbable tissue compatible material, said patch having a tissue-facing surface and a top surface; an optional hemostatic agent that is disposed on said tissue-facing surface or optionally dispersed throughout said patch or optionally as a separate carrier layer, and at least one aperture or slit that penetrates said patch at least partially from said tissue-facing surface to said top surface. | 2015-10-22 |
20150297787 | ANTIMICROBIAL COMPOSITION COMPRISING PYROGENIC SILICA AND SERRATHIOPEPTIDASE AND USES THEREOF - Methods are provided for treatment of wounds using a complex antimicrobial sorption composition possessing the necrolytic effect for treating the purulent wounds, the trophic ulcers, the wounds, and the infiltrates with the significant necrotic and exudative components represents the silica sorbent with the immobilized drug. Pyrogenic silica is used as a siliceous sorbent, and serrathiopeptidase as a drug. | 2015-10-22 |
20150297788 | POLYHEDRAL OLIGOMERIC SILSESQUIOXANE (POSS)-BASED BIOACTIVE HYBRID GLASS AS A SCAFFOLD FOR HARD TISSUE ENGINEERING - A hybrid bioactive glass comprising a plurality of POSS-cages each having at least one flexible arm radiating from an Si atom of the POSS-cage, each POSS-cage being covalently linked to another POSS-cage through an Si—O—Si linkage between two flexible arms. A method of forming a hybrid bioactive glass comprising the steps of providing a plurality of POSS-cages, each having at least one reactive flexible arm radiating from an Si atom detailed by —X—Si[R | 2015-10-22 |
20150297789 | NON-TOXIC CROSS-LINKER FOR Hyaluronic ACID - Systems and methods are disclosed for cosmetic augmentation by storing a non-toxic biocompatible cross-linker; storing a biocompatible polymer having a multi-phase mixture with a predetermined controlled release of selected pharmaceutical substance to modulate soft tissue response to the polymer; mixing the biocompatible cross-linker and polymer into a mixture; injecting the mixture into a patient and during or after injection, cross-linking the polymer in the patient; and augmenting soft tissue with the biocompatible cross-linked polymer. | 2015-10-22 |
20150297790 | HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINE - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 2015-10-22 |
20150297791 | Multilayer Fibrous Polymer Scaffolds, Methods of Production and Methods of Use - Fibrous polymer scaffolds and methods of manufacture are provided. The scaffolds can be formed of multiple layers and the extent and direction of alignment of each layer can be controlled. Efficient fabrication systems and methods for producing such scaffolds include apparatuses and processes are also provided. Kits including the fibrous polymer scaffolds and methods for implanting such scaffolds are also provided. | 2015-10-22 |
20150297792 | DEMINERALIZED CANCELLOUS STRIP DBM GRAFT - An osteoimplant includes at least partially demineralized cancellous bone as a substrate, which is impregnated with demineralized cortical bone. matrix (DBM). The implant may include a binding agent to adhere the DBM to the cancellous bone substrate, and may also include a soft tissue barrier that covers a portion of the external surface of the implant. The cancellous bone substrate may be selectively demineralized, so as to provide regions with greater malleability, and other regions with greater structural properties. | 2015-10-22 |
20150297793 | DEMINERALIZED BONE MATRIX WITH IMPROVED OSTEOINDUCTIVITY - Methods of making and osteoinductive compositions are provided. The method includes mixing isolated periosteum tissue with a demineralized bone matrix to form the osteoinductive composition. The periosteum tissue is isolated from the surface of large bones such as femur, tibia, humerus or a mixture thereof. The demineralized bone matrix can include a plurality of surface demineralized or fully demineralized bone fibers, bone chips, bone particles or mixtures thereof. In the osteoinductive composition the substantially isolated periosteum tissue is from about 0.5% wt. to about 10% wt. A method for repairing a bone defect is also provided. The method of treatment includes applying to the bone defect a substantially effective amount of a mixture of isolated periosteum tissue and demineralized bone matrix. | 2015-10-22 |
20150297794 | METHOD FOR PRODUCING MIXED CELL POPULATION OF CARDIOMYOCYTES AND VASCULAR CELLS FROM INDUCED PLURIPOTENT STEM CELL - The present invention provides: a method for producing mixed cells comprising cardiomyocytes, endothelial cells and mural cells from induced pluripotent stem cells, the method comprising (a) a step of producing cardiomyocytes from induced pluripotent stem cells and (b) a step of culturing the cardiomyocytes in the presence of VEGF; and a therapeutic agent for heart diseases, comprising the mixed cells produced by the method. | 2015-10-22 |
20150297795 | CARRIER FOR TRANSFERRING CELL SHEET FOR TRANSPLANTATION - The object is to provide a carrier showing superior adhesion property and detachability, which is suitable for transferring a cell sheet. A carrier for transferring a cell sheet for transplantation comprising a cell sheet-adhesive coating layer that can respond to a non-cytotoxic condition and a support layer consisting of a base material acceptable as a medical material is provided. By applying a cell sheet adhering to the coating layer of the carrier to a transplantation site and providing the non-cytotoxic condition, the carrier can be detached and removed with maintaining the cell sheet at the transplantation site. | 2015-10-22 |
20150297796 | STENTS WITH RADIOPAQUE MARKERS - Various embodiments of stents with radiopaque markers arranged in patterns are described herein. | 2015-10-22 |
20150297797 | Coating Formulations for Scoring or Cutting Balloon Catheters - The present invention is related to scoring or cutting balloon catheters carrying at least on a portion of their surface at least one oxidation-insensitive drug or oxidation-insensitive polymer-free drug preparation and at least one lipophilic antioxidant at a ratio of 3-100% by weight of the at least one lipophilic antioxidant in relation to 100% by weight of the drug, wherein the at least one oxidation-insensitive drug is selected of taxanes, thalidomide, statins, corticoids and lipophilic derivatives of corticoids, and the at least one lipophilic antioxidant is selected of nordihydroguaiaretic acid, resveratrol and propyl gallate. | 2015-10-22 |
20150297798 | Extracellular Matrix Mesh Coating - Provided are surgical meshes embedded in a gelled, solubilized extracellular matrix (ECM) composition, methods of making the same, and methods of using the same to repair defects in a body. The surgical mesh may be a synthetic polymer such as polypropylene, and the ECM coating reduces the foreign body response and scarring at the site of implantation. The device is useful for repairing hernias, pelvic floor disorders, and in breast reconstructions. | 2015-10-22 |
20150297799 | Methods And Compositions For The Treatment Of Open And Closed Wound Spinal Cord Injuries - Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes that may be used for the treatment of spinal cord injuries. In addition, other embodiments are directed to polymeric “fill-in” bandages that may be used for the treatment of spinal cord injuries. For example, an erodible, or biodegradable, form of biocompatible polymer of the present invention is fabricated for surgical implantation into the site of the spinal cord injury. | 2015-10-22 |
20150297800 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS - A vessel including a thermoplastic wall enclosing a lumen is disclosed. The wall supports an SiO | 2015-10-22 |